Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study

Table 3 Associations between cervical HPV DNA, HIV-1 serostatus and cytology and incident genital warts among a sub-group of 306 women

Characteristic	Number of events/person-years	Unadjusted HR^a(95% CI)	Adjusted HR^b(95% CI)	P-value
Cervical HPV DNA at baseline
HPV-6 positive, yes vs. no
Effect in 1^st year of follow-up	4/17	8.67 (1.86-40.40)	9.09 (1.75-47.29)	0.009
Effect after 1^st year of follow-up	1/12	0.12 (0.03-0.54)	0.11 (0.02-0.57)	0.009
HPV-11 positive, yes vs. no	1/21	0.74 (0.07-7.58)	1.17 (0.11-12.37)	0.89
HPV-52 positive, yes vs. no	9/50	3.73 (1.28-10.83)	3.81 (0.90-16.23)	0.07
Other HPV types, negative for types 6, 11,52	19/226	1.48 (0.64-3.45)	2.64 (0.62-11.33)	0.19
Cervical cytology at baseline (N = 296)
Normal	9/369	1.0	1.0
ASCUS/LSIL/HSIL	23/134	7.38 (3.10-17.56)	3.05 (1.17-7.92)	0.02
HIV status, nadir CD4+ count
HIV seronegative	4/289		1.0
HIV-1+, CD4 >200cells/μL	11/119		3.22 (0.71-14.59)	0.13
HIV-1+, CD4 ≤200 cells/μL	18/79		10.94 (2.60-46.12)	0.001

Note. HR: hazard ratio; CI, confidence interval; ASCUS, atypical squamous changes of unknown significance; LSIL/HSIL, low/high squamous intraepithelial lesions.
^a Determined by Cox regression with shared frailty; ^b Model also included age group, history of pregnancy, history of smoking, hormonal contraception, education less than or greater than primary and number of sexual partners in past week. For those factors not conforming to proportional hazards, a parameter was added to determine the impact in the first year of follow-up compared to after one year.

ISSN: 1471-2334